Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.

12 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 4 tests: 4 consistent, 0 inconsistent, 4 via agent-written checks.

7 copyedit issues flagged: mostly consistency, clarity, grammar.

Checked 33 references: 21 verified — 12 not checked.

2 data/code links checked; 2 live.

Ready after substantive revision. The three critical gaps (key resources identification, ethics statement, and code sharing) must be addressed before submission; the missing ethics details and drug manufacturer information are likely to be flagged by journal editors and reviewers. Other medium-priority improvements will strengthen the manuscript's overall quality and completeness.

1. 1.
   HIGHethics

   Add the name(s) of the IRB/ethics committee(s) that approved the protocol, with approval number(s), in the Methods section.

   A named IRB with approval number is a standard requirement for clinical trial reporting; its absence is a major reporting gap.
2. 2.
   HIGHethics

   Add an explicit statement that all participants provided written informed consent before enrollment, in the Methods section.

   Informed consent is a fundamental ethical requirement and must be explicitly stated for human interventional trials.
3. 3.
   HIGHrigor

   Provide the manufacturer, catalog number/RRID, and lot number for bimagrumab and semaglutide in the Reagents section.

   Without source identification, the investigational products cannot be reproduced or verified, which is a key resource requirement.
4. 4.
   HIGHstatistics

   Specify the version of SAS (and any other software) used for statistical analysis in the main text of the Methods section.

   Software version is essential for reproducibility; currently it is only mentioned in the supplementary reporting summary.
5. 5.
   HIGHdata code

   Add a code availability statement indicating whether custom analysis code was used and, if so, provide a repository link (e.g., GitHub with DOI).

   Code sharing is expected for transparency, even in clinical trials; if no custom code was used, state that explicitly.
6. 6.
   HIGHreporting

   Mention adherence to CONSORT 2010 (or applicable reporting guideline) and indicate where the completed checklist is available (e.g., Supplementary Material).

   Journals strongly encourage reporting guideline checklists to ensure transparent and complete reporting.
7. 7.
   HIGHreporting

   Add a sentence in the Results or a dedicated table explicitly confirming that all pre-specified primary and secondary outcomes are reported, including those with null results.

   Selective outcome reporting is a common bias; an explicit statement improves transparency and trust.
8. 8.
   HIGHreporting

   Add a formal Limitations section (or paragraph) in the Discussion that explicitly discusses the open-label design for semaglutide, the lack of multiplicity adjustment, and the post-hoc nature of week 72 analyses.

   While limitations are mentioned, a consolidated discussion demonstrates thoroughness and appropriate caution in interpretation.
9. 9.
   HIGHrigor

   Define what constitutes an outlier and describe how outliers were handled (or note that no outlier removal was performed) in the Statistical analysis section.

   Outlier handling is a sub-criterion of study design; its absence is a minor gap that reviewers will note.
10. 10.
    MEDIUMrigor

    Provide a more detailed power analysis that states the assumed effect size per comparison or explains the basis for the 5% treatment effect used across groups.

    A per-comparison power analysis would strengthen the study design description and justify sample size for multiple arms.
11. 11.
    MEDIUMcopyedit

    In Table 1, check the hsCRP mean (3.0) and SD (121.1) for plausibility; if correct, consider reporting as geometric mean (CV%) for consistency with other skewed parameters.

    The extremely high SD relative to the mean suggests severe skew; alternative presentation is standard for inflammatory markers.
12. 12.
    MEDIUMcopyedit

    In Table 2 footnote, change 'P < .001' to 'P < 0.001' for numeric consistency.

    Consistent formatting of p-values across the manuscript is a minor but expected standard.
13. 13.
    MEDIUMcopyedit

    In the Methods (Statistical analysis), briefly define 'intercurrent events' when first mentioned, for readers unfamiliar with ICH E9(R1).

    Defining technical terms improves readability and accessibility to a broader audience.
14. 14.
    LOWstatistics

    For the primary endpoint (bimagrumab 10 mg/kg + semaglutide 2.4 mg vs placebo), consider reporting the exact p-value instead of '<0.001' if available from the output.

    Exact p-values, even if extremely small, allow readers to assess precision; this is a minor point for journals that prefer exact values.
15. 15.
    LOWrigor

    In the Statistical analysis section, add a brief justification that normality and equal variance assumptions are reasonable given the large sample size and planned use of MMRM with unstructured covariance.

    Explicitly addressing statistical assumptions, even briefly, strengthens the statistical methods description.